Syed Abutalib, MD
Most patients with newly diagnosed Burkitt lymphoma are treated with intensive, frequent multiagent regimens with excellent outcomes. The findings of an ongoing multicenter study suggest that some patients can experience excellent outcomes with a less-intensive chemoimmunotherapy regimen of etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin with rituximab that is dose-adjusted for risk (DA-EPOCH-R).
Preliminary results of the DA-EPOCH-R study were presented at